Abstracts tagged "giant cell arteritis"

Abstract Number: 0739 • ACR Convergence 2025
Tocilizumab in Giant Cell Arteritis with ischemic vs non-ischemic manifestations
Carmen Secada-Gómez¹, Javier Loricera², Clara Moriano³, Santos Castañeda⁴, Javier Narváez⁵, Vicente Aldasoro Cáceres⁶, Olga Maiz⁷, Rafael B. Melero-González⁸, Paloma Vela Casasempere⁹, Susana Romero-Yuste¹⁰, Jose Luis Callejas¹¹, Eugenio de Miguel¹², Eva Galíndez Agirregoikoa¹³, Francisca Sivera¹⁴, Ivan Ferraz Amaro¹⁵, Julio Sánchez Martín¹⁶ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Hospital León, LEON, Castilla y Leon, Spain, ⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷Hospital Universitario de Donosti, Donostia, Spain, ⁸COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁹Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁰University Hospital Complex of Pontevedra, Pontevedra, Spain, ¹¹Department of Internal Medicine, Hospital San Cecilio, Granada, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁴Hospital General Universitario Elda, Elda, Spain, ¹⁵Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁶Hospital Universitario ¹² de Octubre, Madrid, Spain
Background/Purpose: Tocilizumab (TCZ) is the only approved biological drug in the treatment of giant cell arteritis (GCA). However, there are no comparative studies on the…
Abstract Number: 2526 • ACR Convergence 2025
Infection Risk Associated with Steroid-Sparing Therapies in GCA, PMR, and ANCA-Associated Vasculitis: A Systematic Review
Divya Sudireddy¹, Brent Leung², Jean Liew³, Tuhina Neogi⁴, David Felson³, Michael LaValley⁵ and David Flynn², ¹Boston Medical Center, Westborough, MA, ²Boston University, Boston, ³Boston University, Boston, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Boston University School of Public Health, Arlington, MA
Background/Purpose: Giant cell arteritis (GCA), polymyalgia rheumatica (PMR), and ANCA-associated vasculitis (AAV) often require long-term glucocorticoid (GC) therapy, increasing the risk of infections, particularly in…
Abstract Number: 0896 • ACR Convergence 2025
Does complement product C5a and its receptor C5a receptor 1 play a role in giant-cell arteritis?
marc Corbera-bellalta¹, Nuria Farran-Centelles², Nina Visocnik¹, Sergio Prieto-Gonzalez³, Jose hernandez-rodriguez⁴, javier Marco-hernandez⁵, Georgina Espigol-Frigolé¹ and Maria Cid⁶, ¹Hospital Clínic. University of Barcelona. IDIBAPS., Barcelona, Spain, ²Autoimmune diseases, Barcelona, Spain, ³Hospital Clinic, Barcelona, Catalonia, Spain, ⁴Hospital Clinic. University of Barcelona. IDIBAPS, Barcelona, Catalonia, Spain, ⁵Hospital Clinic.University of Barcelona. IDIBAPS, Barcelona, Catalonia, Spain, ⁶Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: Patients with giant-cell arteritis (GCA) are in an unmet need for reduction of GC exposure because of the high incidence of GC-related side effects…
Abstract Number: 0754 • ACR Convergence 2025
Is There a Seasonal Pattern in Giant Cell Arteritis? Revisiting the Evidence in a Large Monocentric Cohort of 1203 patients
Milena Bond¹, Philipp Bosch², Aaron Juche³, Hans Bastian³ and Wolfgang Schmidt⁴, ¹South Tyrol Health Trust and Teaching Hospital of the Paracelsus Medical University, Brunico, Italy, ²Medical University of Graz, Graz, Austria, ³Rheumaklinik Berlin-Buch, Berlin, Germany, ⁴Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany
Background/Purpose: Whether the disease onset in giant cell arteritis (GCA) exhibits a seasonal pattern remains unclear. Previous studies have yielded conflicting evidence: some report no…
Abstract Number: 0738 • ACR Convergence 2025
Real World Steroid Burden, Treatment Patterns, and Rheumatologists’ Perceptions on Advanced Therapy in Giant Cell Arteritis
Anisha Dua¹, Aditi Kadakia², Patrick Zueger³, Simran Marwaha⁴, Nathaniel Zerad³, Arathi Setty³, William Jones⁴ and Valerie Devauchelle⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²AbbVie Inc, Woburn, MA, ³AbbVie Inc, North Chicago, IL, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵UBO, Brest, France
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in patients 50 years and older. Glucocorticoids (GC) are the mainstay of treatment for GCA…
Abstract Number: 2109 • ACR Convergence 2025
Comparative Effects of IL-6 inhibition, Methotrexate, and Glucocorticoid Monotherapy on Bone Mineral Density, 3D-DXA femoral structure and Bone Turnover Markers in GCA and PMR
Edgar Wiebe¹, Lien Meerkatt², Andriko Palmowski³, Zhivana Boyadzhieva⁴, Kerstin Rubarth⁵, Sandra Hermann¹, Burkhard Muche³, Gerhard Krönke⁶ and FRANK BUTTGEREIT⁷, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁵Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁷Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Individuals with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are at increased risk for osteoporosis and fragility fractures due to long-term glucocorticoid (GC)…
Abstract Number: 0895 • ACR Convergence 2025
Impact of Glucocorticoid Tapering in Giant Cell Arteritis: Analysis From the SELECT-GCA Trial
FRANK BUTTGEREIT¹, Kevin Winthrop², Leonard Calabrese³, Ivan Lagunes⁴, Aditi Kadakia⁵, Ana Romero⁶, Shaofei Zhao⁴, Weihan Zhao⁴, Arathi Setty⁴ and Jeffrey Curtis⁷, ¹Charité University Medicine Berlin, Berlin, Berlin, Germany, ²Oregon Health & Science University, Portland, OR, ³Cleveland Clinic, Cleveland, OH, ⁴Abbvie Inc, North Chicago, IL, ⁵AbbVie Inc, Woburn, MA, ⁶AbbVie, Barcelona, Spain, ⁷University of Alabama at Birmingham, Birmingham
Background/Purpose: This study assessed the occurrence of adverse events of serious infections, herpes zoster, and opportunistic infection during concomitant treatment with GCs and after GC…
Abstract Number: 0753 • ACR Convergence 2025
Incidence of Ischemic Vision Loss Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Mary Peng¹, Kylie Carlson², Sebastian E Sattui³ and Michael Putman⁴, ¹Medical College of Wisconsin, Wauwatosa, WI, ²Medical College of Wisconsin, Milwaukee, WI, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Ischemic vision loss affects up to one quarter of patients with giant cell arteritis (GCA). The incidence of ischemic vision loss among patients with…
Abstract Number: 0735 • ACR Convergence 2025
A Real-World Study from the Greater Paris Clinical Data Warehouse
Aïcha Kante¹, Olivier Hassanaly², Geoffroy Peyrac³, David Saadoun⁴, Cacoub Patrice⁴, Alexis REGENT⁵, Benjamin Terrier⁶, Luc Mouthon⁷, Arsène Mekinian⁸, Karim Sacré⁹, Jean-François Alexandra¹⁰, Sébastien Abad¹¹, Robin Dhote¹¹, Cécile goujard¹², Damien Sène¹³, Stéphane Mouly¹⁴, Baptiste Hervier¹⁵, Olivier Bory¹⁶, Elisabeth Aslangul¹⁶, Isabelle Mahé¹⁶, Anne Couvelard¹⁷, Yann Nguyen¹⁸, Agnès Lefort¹⁸, Sophie georgin-Lavialle¹⁹, Olivier Steichen¹⁹, Viet-Thi Tran²⁰ and Cloé Comarmond¹, ¹Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ²Unité de recherche clinique, AP-HP, Hôpital Saint Louis, F⁷⁵⁰¹⁰, Paris, France, Paris, France, ³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁴Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ⁵Hopital Cochin, Paris, France, ⁶Cochin Hospital, Paris, France, ⁷Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁸Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ⁹Department of Internal Medicine, Bichat University Hospital, Université Paris Cité, AP-HP, Paris, France, Paris, France, ¹⁰Internal Medicine, Hôpital Bichat, APHP, Paris, France, ¹¹Service de Médecine Interne, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP); Université Paris ¹³, Sorbonne Paris Cité, Bobigny, France, Bobigny, France, ¹²Université Paris Saclay, Department of Internal Medicine and Clinical Immunology, Bicêtre Hospital, APHP, UMR¹¹⁸⁴ Inserm, CEA, Le Kremlin Bicêtre, France, Kremlin Bicêtre, France, ¹³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, Ile-de-France, France, ¹⁴Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France, ¹⁵Internal Medicine Department, Hôpital Saint-Louis, AP-HP, Université Paris Cité, Paris, France., Paris, France, ¹⁶Department of Internal Medicine, Louis-Mourier Hospital, AP-HP, Colombes, France, Colombes, France, ¹⁷Pathology Department, Bichat and Beaujon Hospitals, AP-HP, FHU MOSAIC, Université Paris Cité, Paris, France, Paris, France, ¹⁸Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ¹⁹Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ²⁰Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAe, Centre for Research in Epidemiology and Statistics (CRESS), Paris; and Centre d'Epidémiologie Clinique, Hôpital Hôtel-Dieu, AP-HP, Paris, France, Paris, France
Background/Purpose: Giant cell arteritis (GCA) relapses are frequent and often require therapeutic intensification in the form of glucocorticoids (GC) increase. GCA management has significantly evolved…
Abstract Number: 1910 • ACR Convergence 2025
Clinical profile and healthcare resource utilization of patients diagnosed with giant cell arteritis or polymyalgia rheumatica in the US: a real-world cohort study using a large database of administrative health claims
Julie Mouchet¹, Tim Nguyen², Valeria Jordan M.³, G S Ramakrishna⁴, Linda Grinnell-Merrick², Andrew Heaney⁵, Anushka Mitra Das⁵, Pooja Shah⁶ and Evi Zhuleku⁷, ¹Novartis Pharma AG, Basel, Switzerland, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, Tenafly, NJ, ⁴Novartis Healthcare Private Limited, Hyderabad, India, ⁵Novartis Ireland Ltd, Dublin, Ireland, ⁶Cytel Inc, Cambridge, ON, Canada, ⁷Cytel Inc, Berlin, Germany
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are systemic inflammatory conditions which predominantly affect individuals over the age of 50 years. The conditions…
Abstract Number: 0893 • ACR Convergence 2025
Transcriptomic insights into GCA compared to clinically diverse controls: Inflammation, Aging, Therapeutic Targets and the role of SPP1 in the temporal artery
Ingrid Lindquist¹, Alisha Eskew², Dongsoek Choi³, David Wilson⁴, Diva Salomao⁵, Hillary Stiefel⁴, Daniel Albert⁴, Kiana Vakil-Gilani⁶, Daniela Ghetie⁷, James Rosenbaum⁸ and Marcia Friedman⁹, ¹Portland VA Medical Center, Portland, OR, ²OHSU, Portland, OR, ³OHSU, Portland, ⁴Casey Eye Institute OHSU, Portland, OR, ⁵Mayo Clinic, Rochester, MN, ⁶PeaceHealth, Portland, OR, ⁷OHSU, Lake Oswego, OR, ⁸Legacy Devers Eye Institute, Portland, OR, ⁹Immpact Bio, Beaverton, OR
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in people over 50 years old and is a clinical diagnosis bolstered by non-specific inflammatory…
Abstract Number: 0752 • ACR Convergence 2025
Characterization of patients with polymyalgia rheumatica in the ARTESER giant cell arteritis cohort
Maite Silva-Diaz¹, Marta Domínguez-Álvaro², Rafael B. Melero-González³, Elisa Fernández-Fernández⁴, Jesús Alejandro Valero⁵, Ismael González⁶, Julio Sánchez Martín⁷, Javier Narváez⁸, Eva Galíndez Agirregoikoa⁹, Vicente Aldasoro Cáceres¹⁰, lydia Abasolo Alcazar¹¹, Javier Loricera¹², Noemí Garrido¹³, Santos Castañeda¹⁴, Carlota L Iñiguez¹⁵, Alicia Garcia¹⁶, Clara Molina Almela¹⁷, María Alcalde Villar¹⁸, Antonio Juan Mas¹⁹ and Ricardo Blanco²⁰, ¹Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Hospital Universitario Donosti, Donosti, Spain, ⁶Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ⁷Hospital Universitario ¹² de Octubre, Madrid, Spain, ⁸Hospital Universitario de Bellvitge, Barcelona, Spain, ⁹BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁰Hospital Universitario de Navarra, Pamplona, Spain, ¹¹IdISSC. HCSC, Madrid, Madrid, Spain, ¹²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ¹³Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ¹⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁵Hospital del Bierzo, Ponferrada, Castilla y Leon, Spain, ¹⁶Rheumatologist, La Laguna, Spain, ¹⁷Consorci Hospital General Universitari de València, Valencia, Spain, ¹⁸Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain, Madrid, Spain, ¹⁹Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain, ²⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Giant cell arteritis (GCA) is a chronic granulomatous vasculitis affecting medium- and large-sized arteries (1). The classic symptoms are cranial symptoms, including headache, jaw…
Abstract Number: 0734 • ACR Convergence 2025
Glucocorticoid Exposure and Comorbidity Profile in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: a multi-country cohort study
Julie Mouchet¹, Lauren Revie², Tim Nguyen³, Liwei Zhao⁴, Valeria Jordan M.⁵, G S Ramakrishna⁶, Linda Grinnell-Merrick³, Atif Adam⁷ and Minouk Schoemaker⁸, ¹Novartis Pharma AG, Basel, Switzerland, ²IQVIA, EMEA, London, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴IQVIA, Real World Solutions, Mölndal, Sweden, ⁵Novartis Pharmaceuticals Corporation, Tenafly, NJ, ⁶Novartis Healthcare Private Limited, Hyderabad, India, ⁷IQVIA Inc, Boston, ⁸IQVIA, Real World Solutions, Amsterdam, Netherlands
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are systemic inflammatory conditions that predominantly affect individuals ≥50 years of age. The conditions share overlapping…
Abstract Number: 1900 • ACR Convergence 2025
Capturing Patient Cohorts: A Temporal Arteritis Classifier
Megan Sullivan¹, Joseph Rosen¹, Christopher Grilli¹, Kenneth Warrington² and Victor E Ortega¹, ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic, ROCHESTER, MN
Background/Purpose: Giant cell arteritis (GCA) is a granulomatous vasculitis affecting cranial and large arteries in individuals over 50 years of age. Its relative rarity poses…
Abstract Number: 0720 • ACR Convergence 2025
Current State of Racial, Ethnic, Sex, and Geographical Diversity in ANCA-associated vasculitis and Giant Cell Arteritis Trials
Manuel Carpio Tumba¹, Aida Mohamadi², Diana Louden³, Victor Pimentel-Quiroz⁴, Michael Putman⁵, Didem Saygin⁶, Raisa Lomanto Silva⁷ and Sebastian E Sattui⁸, ¹University of Pittsburgh, Pittsburgh, PA, ²Tehran University of Medical Sciences, Tehran, Iran, ³University of Washington, Seattle, WA, ⁴Universidad Científica del Sur, San Isidro, Peru, ⁵The Medical College of Wisconsin, Milwaukee, WI, ⁶Rush University Medical Center, Chicago, IL, ⁷Massachusetts General Hospital, Boston, MA, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Randomized controlled trials (RCTs) generate unbiased efficacy estimates and are required for regulatory approval. Understanding the degree to which they include racial, ethnic, sex,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].